Xbrane Biopharma AB
F:7XB
Xbrane Biopharma AB
F:7XB
Price:
1.037
EUR
10.26%
Market Closed
Market Cap:
€30.3m
Balance Sheet
Balance Sheet Decomposition
Xbrane Biopharma AB
Xbrane Biopharma AB
Balance Sheet Decomposition is not available for
Xbrane Biopharma AB
Xbrane Biopharma AB
Balance Sheet
Xbrane Biopharma AB
Xbrane Biopharma AB
Currency: SEK
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
0
|
9
|
6
|
31
|
8
|
101
|
164
|
243
|
295
|
194
|
65
|
124
|
|
| Cash |
0
|
0
|
0
|
0
|
8
|
101
|
164
|
243
|
295
|
194
|
65
|
124
|
|
| Cash Equivalents |
0
|
9
|
6
|
31
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
5
|
7
|
16
|
21
|
6
|
58
|
50
|
47
|
34
|
34
|
|
| Accounts Receivables |
0
|
0
|
0
|
1
|
8
|
10
|
0
|
51
|
42
|
1
|
0
|
17
|
|
| Other Receivables |
0
|
0
|
4
|
5
|
8
|
10
|
6
|
7
|
8
|
46
|
34
|
17
|
|
| Inventory |
0
|
0
|
0
|
2
|
3
|
6
|
0
|
0
|
0
|
50
|
107
|
247
|
|
| Other Current Assets |
0
|
0
|
0
|
3
|
1
|
34
|
78
|
73
|
216
|
222
|
255
|
201
|
|
| Total Current Assets |
1
|
7
|
7
|
44
|
28
|
162
|
248
|
374
|
561
|
514
|
462
|
606
|
|
| PP&E Net |
0
|
0
|
10
|
18
|
19
|
17
|
16
|
14
|
74
|
71
|
88
|
65
|
|
| PP&E Gross |
0
|
0
|
10
|
0
|
19
|
17
|
16
|
14
|
74
|
71
|
88
|
65
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
6
|
10
|
18
|
20
|
13
|
20
|
29
|
39
|
|
| Intangible Assets |
0
|
0
|
6
|
7
|
6
|
6
|
5
|
4
|
50
|
102
|
100
|
168
|
|
| Goodwill |
0
|
0
|
52
|
56
|
57
|
60
|
61
|
58
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
1
|
1
|
9
|
9
|
13
|
4
|
4
|
4
|
4
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
52
|
56
|
57
|
60
|
61
|
58
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1
N/A
|
7
+856%
|
75
+1 026%
|
125
+66%
|
111
-11%
|
253
+128%
|
339
+34%
|
464
+37%
|
688
+48%
|
691
+0%
|
654
-5%
|
842
+29%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
0
|
5
|
2
|
11
|
31
|
21
|
30
|
41
|
23
|
31
|
243
|
|
| Accrued Liabilities |
0
|
0
|
0
|
3
|
6
|
84
|
112
|
156
|
66
|
66
|
135
|
41
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
45
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
2
|
8
|
9
|
76
|
96
|
|
| Other Current Liabilities |
0
|
0
|
8
|
0
|
1
|
1
|
3
|
1
|
105
|
138
|
85
|
158
|
|
| Total Current Liabilities |
1
|
0
|
23
|
6
|
18
|
161
|
140
|
189
|
220
|
237
|
327
|
538
|
|
| Long-Term Debt |
0
|
0
|
0
|
2
|
1
|
0
|
6
|
4
|
36
|
29
|
156
|
96
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
4
|
3
|
4
|
8
|
9
|
13
|
1
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
0
-35%
|
28
+7 021%
|
11
-61%
|
23
+109%
|
170
+653%
|
155
-9%
|
206
+33%
|
257
+25%
|
266
+3%
|
482
+82%
|
634
+31%
|
|
| Equity | |||||||||||||
| Common Stock |
0
|
0
|
1
|
1
|
1
|
1
|
3
|
5
|
6
|
6
|
7
|
343
|
|
| Retained Earnings |
8
|
11
|
26
|
50
|
93
|
102
|
267
|
521
|
708
|
876
|
1 264
|
1 530
|
|
| Additional Paid In Capital |
8
|
17
|
73
|
163
|
180
|
184
|
448
|
774
|
1 134
|
1 294
|
1 429
|
1 395
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
6
+6 198%
|
48
+654%
|
114
+140%
|
88
-22%
|
83
-6%
|
184
+122%
|
258
+40%
|
432
+68%
|
425
-2%
|
171
-60%
|
209
+22%
|
|
| Total Liabilities & Equity |
1
N/A
|
7
+856%
|
75
+1 026%
|
125
+66%
|
111
-11%
|
253
+128%
|
339
+34%
|
464
+37%
|
688
+48%
|
691
+0%
|
654
-5%
|
842
+29%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
21
|
21
|
21
|
44
|
55
|
59
|
136
|
196
|
221
|
243
|
263
|
1 529
|
|
Switch to:
Switch to:
See Also
Discover More
